The broad long-term objectives of this proposal are two -fold:.(l) to elucidate novel endogenous pathways for anti-inflammatory lipid mediators (LM) and 2) assess their contributions to human health and disease. Oxidized lipids that act on human neutrophil (PMN) are generally considered as """"""""proinflammatory mediators."""""""" In this project, the investigator found that certain mediators such as lipoxins (LX) possess down-regulatory actions in key events in inflammation and reperfusion injury. Aspirin (ASA) treatment actually trigger formation l5 epimeric lipoxins (ATL) that may underlie some of ASA's beneficial effects in vascular disease and cancer by pirating LX signaling.: In work in progress, the investigator found that ASA also triggers two novel pathways from eicosapentanoic acid (EPA, a major fish oil). Since ASA and dietary supplements of EPA are widely used in the U.S., it is important to elucidate anti-inflammatory factions on PMN. The investigator proposes the following novel hypothesis: Aspirin pirates function of natural counterregulatory lipid mediators during PMN interactions with inflamed and hypoxic endothelial cells. These local mediators mimic native LX at their PMN receptors, and other new compounds the investigator isolated antagonize proinflammatory leucotriene receptors. They down -regulate PMN and mimic navel endogenous """"""""anti-inflammatory"""""""" lipid mediated circuits. To test this, four specific aims are proposed:
Aim 1 will elucidate the novel aspirin-triggered lipid mediators (ATLM) derived from EPA :during endothelial-PMN interactions and their routes of formation. A second series examines formation by hypoxic cells. The ability of ATLM to block PMN will be established and ranked.
Aim 2 addresses the recognition of novel ATLM and IX stable analogs by LXA4 and 1eucotriene B4 (LTB4) receptors using recombinant as well as receptor chimeras to determine mimetic/antagonist properties, and Aim 3 focuses on activation of these receptors by ATLM and other novel ligands.
Aim 4 will focus on the impact of ATLM in inflammation and repefusion injury using transgenic mice overexpressing LXA4 receptors or LTB4 receptors to determine whether these circuits are responsible for the anti-inflammation. ATLM generation will be examined in these mice given EPA and ASA treatment. Completion of these aims will provide a new paradigm to address inflammatory diseases, namely by elucidating endogenous lipid mediators of anti-inflammation.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37GM038765-20
Application #
7122514
Study Section
Special Emphasis Panel (NSS)
Program Officer
Okita, Richard T
Project Start
1987-07-01
Project End
2010-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
20
Fiscal Year
2006
Total Cost
$412,976
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sorokin, Alexander V; Norris, Paul C; English, Justin T et al. (2018) Identification of proresolving and inflammatory lipid mediators in human psoriasis. J Clin Lipidol 12:1047-1060
Halade, Ganesh V; Norris, Paul C; Kain, Vasundhara et al. (2018) Splenic leukocytes define the resolution of inflammation in heart failure. Sci Signal 11:
Halade, Ganesh V; Kain, Vasundhara; Serhan, Charles N (2018) Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. FASEB J 32:3717-3729
Fedirko, Veronika; McKeown-Eyssen, Gail; Serhan, Charles N et al. (2017) Plasma lipoxin A4 and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. Mol Carcinog 56:1977-1983
Dalli, Jesmond; Colas, Romain A; Arnardottir, Hildur et al. (2017) Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTR1 Controls Infection Resolution. Immunity 46:92-105
Diaz, Luis Alonso; Altman, Norman H; Khan, Wasif et al. (2017) Specialized Proresolving Mediators Rescue Infant Mice from Lethal Citrobacter rodentium Infection and Promote Immunity against Reinfection. Infect Immun 85:
ReƔtegui, Eduardo; Jalali, Fatemeh; Khankhel, Aimal H et al. (2017) Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming. Nat Biomed Eng 1:
ChiurchiĆ¹, Valerio; Leuti, Alessandro; Dalli, Jesmond et al. (2016) Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med 8:353ra111
Zhu, Mingqin; Wang, Xiuzhe; Hjorth, Erik et al. (2016) Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase A?42 Phagocytosis. Mol Neurobiol 53:2733-49
Wang, Chin-Wei; Colas, Romain A; Dalli, Jesmond et al. (2015) Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. Infect Immun 84:658-65

Showing the most recent 10 out of 59 publications